BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nielsen OH, Loftus EV, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med. 2013;11:174. [PMID: 23902720 DOI: 10.1186/1741-7015-11-174] [Cited by in Crossref: 80] [Cited by in F6Publishing: 66] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Cao RH, Grimm MC. Pregnancy and medications in inflammatory bowel disease. Obstet Med 2021;14:4-11. [PMID: 33995565 DOI: 10.1177/1753495X20919214] [Reference Citation Analysis]
2 Narayan B, Nelson-Piercy C. Medical problems in pregnancy. Clin Med (Lond) 2017;17:251-7. [PMID: 28572227 DOI: 10.7861/clinmedicine.17-3-251] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
3 Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opin Drug Saf 2021;20:275-92. [PMID: 33412078 DOI: 10.1080/14740338.2021.1873948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cunningham MW, Jayaram A, Deer E, Amaral LM, Vaka VR, Ibrahim T, Cornelius DC, LaMarca B. Tumor necrosis factor alpha (TNF-α) blockade improves natural killer cell (NK) activation, hypertension, and mitochondrial oxidative stress in a preclinical rat model of preeclampsia. Hypertens Pregnancy 2020;39:399-404. [PMID: 32646252 DOI: 10.1080/10641955.2020.1793999] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Kammerlander H, Nielsen J, Knudsen T, Kjeldsen J, Friedman S, Nørgård BM. Anti–TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate–severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight: . Inflammatory Bowel Diseases 2017;23:1916-23. [DOI: 10.1097/mib.0000000000001234] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
6 Berns M, Hommes DW. Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opinion on Investigational Drugs 2016;25:129-43. [DOI: 10.1517/13543784.2016.1126247] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
7 Alijotas-reig J, Esteve-valverde E, Ferrer-oliveras R, Llurba E, Gris JM. Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. Clinic Rev Allerg Immunol 2017;53:40-53. [DOI: 10.1007/s12016-016-8596-x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 17.5] [Reference Citation Analysis]
8 Pham-Huy A, Top KA, Constantinescu C, Seow CH, El-Chaâr D. The use and impact of monoclonal antibody biologics during pregnancy. CMAJ 2021;193:E1129-36. [PMID: 34312166 DOI: 10.1503/cmaj.202391] [Reference Citation Analysis]
9 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol 2018;16:99-105. [PMID: 28870657 DOI: 10.1016/j.cgh.2017.08.041] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 13.5] [Reference Citation Analysis]
11 Marder W, Littlejohn EA, Somers EC. Pregnancy and autoimmune connective tissue diseases. Best Pract Res Clin Rheumatol 2016;30:63-80. [PMID: 27421217 DOI: 10.1016/j.berh.2016.05.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
12 Glover LE, Fennimore B, Wingfield M. Inflammatory Bowel Disease: Influence and Implications in Reproduction. Inflamm Bowel Dis 2016;22:2724-32. [PMID: 27537054 DOI: 10.1097/MIB.0000000000000884] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
13 van der Woude CJ, Metselaar HJ, Danese S. Management of gastrointestinal and liver diseases during pregnancy. Gut 2014;63:1014-23. [DOI: 10.1136/gutjnl-2013-305418] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
14 Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci. 2014;1317:32-38. [PMID: 24840548 DOI: 10.1111/nyas.12456] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
15 Gaidos JK, Kane SV. Sexuality, Fertility, and Pregnancy in Crohn's Disease. Gastroenterology Clinics of North America 2017;46:531-46. [DOI: 10.1016/j.gtc.2017.05.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Tsao NW, Lynd LD, Sadatsafavi M, Hanley G, De Vera MA. Patterns of Biologics Utilization and Discontinuation Before and During Pregnancy in Women With Autoimmune Diseases: A Population-Based Cohort Study. Arthritis Care Res 2018;70:979-86. [DOI: 10.1002/acr.23434] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
17 McConnell RA, Mahadevan U. Use of Immunomodulators and Biologics Before, During, and After Pregnancy. Inflamm Bowel Dis. 2016;22:213-223. [PMID: 26444103 DOI: 10.1097/mib.0000000000000596] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
18 Hassid B, Mahadevan U. The use of biologic therapy in pregnancy: a gastroenterologist's perspective. Curr Opin Rheumatol 2014;26:347-53. [PMID: 24625373 DOI: 10.1097/BOR.0000000000000048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 2.4] [Reference Citation Analysis]
19 Lee S, Seow CH, Adhikari K, Metcalfe A. Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications. Aliment Pharmacol Ther 2020;51:544-52. [DOI: 10.1111/apt.15596] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Friedman S, Nørgård B. The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease. Inflamm Bowel Dis 2017;23:1011-8. [PMID: 28346274 DOI: 10.1097/MIB.0000000000001102] [Cited by in Crossref: 57] [Cited by in F6Publishing: 10] [Article Influence: 19.0] [Reference Citation Analysis]
21 Krause ML, Amin S, Makol A. Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. Ther Adv Musculoskelet Dis 2014;6:169-84. [PMID: 25342996 DOI: 10.1177/1759720X14551568] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
22 Seirafi M, de Vroey B, Amiot A, Seksik P, Roblin X, Allez M, Peyrin-biroulet L, Marteau P, Cadiot G, Laharie D, Boureille A, De Vos M, Savoye G, Rahier J, Carbonnel F, Bonaz B, Colombel J, Bouhnik Y. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther 2014;40:363-73. [DOI: 10.1111/apt.12833] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
23 Mao EJ, Mahadevan U. The Debate is Over: Continue Anti-Tumor Necrosis Factor Therapy Throughout Pregnancy. Am J Gastroenterol 2018;113:1590-1. [PMID: 30337704 DOI: 10.1038/s41395-018-0254-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
24 Chaudrey KH, Kane SV. Safety of Immunomodulators and Anti-TNF Therapy in Pregnancy. Curr Treat Options Gastro 2015;13:77-89. [DOI: 10.1007/s11938-014-0037-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
25 Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, Bibby BM, Uldbjerg N, Connell WR, Rosella O, Grosen A, Brown SJ, Kjeldsen J, Wildt S, Svenningsen L, Sparrow MP, Walsh A, Connor SJ, Radford-smith G, Lawrance IC, Andrews JM, Ellard K, Bell SJ. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016;151:110-9. [DOI: 10.1053/j.gastro.2016.04.002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 132] [Article Influence: 33.2] [Reference Citation Analysis]
26 Leung Y, Panaccione R, Ghosh S, Seow CH. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. Can J Gastroenterol Hepatol 2014;28:505-9. [PMID: 25101334 DOI: 10.1155/2014/967598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
27 Komoto S, Motoya S, Nishiwaki Y, Matsui T, Kunisaki R, Matsuoka K, Yoshimura N, Kagaya T, Naganuma M, Hida N. Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan. Intest Res. 2016;14:139-145. [PMID: 27175114 DOI: 10.5217/ir.2016.14.2.139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
28 Ye TY, Mei Y, Bao DN, Zhu YF, Xu XH, Zhu LF. Maternal anti-tumour necrosis factor-α drug use during pregnancy and risk of infection in the offspring: A systematic review and meta-analysis. Dig Liver Dis 2021;53:1112-7. [PMID: 33376073 DOI: 10.1016/j.dld.2020.11.033] [Reference Citation Analysis]
29 Desai RJ, Bateman BT, Huybrechts KF, Patorno E, Hernandez-Diaz S, Park Y, Dejene SZ, Cohen J, Mogun H, Kim SC. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ 2017;356:j895. [PMID: 28264814 DOI: 10.1136/bmj.j895] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 7.8] [Reference Citation Analysis]
30 Sammaritano LR. Contraception and preconception counseling in women with autoimmune disease. Best Pract Res Clin Obstet Gynaecol 2020;64:11-23. [PMID: 31679995 DOI: 10.1016/j.bpobgyn.2019.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Gaidos JK, Kane SV. Overcoming challenges of treating inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol 2016;12:871-8. [PMID: 26981845 DOI: 10.1586/1744666X.2016.1166958] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
32 Zhang M, Wang X, Han MK, Collins JF, Merlin D. Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis. Nanomedicine (Lond) 2017;12:1927-43. [PMID: 28665164 DOI: 10.2217/nnm-2017-0196] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 12.8] [Reference Citation Analysis]
33 Williams M, Chakravarty EF. Rheumatoid arthritis and pregnancy: impediments to optimal management of both biologic use before, during and after pregnancy. Curr Opin Rheumatol. 2014;26:341-346. [PMID: 24663107 DOI: 10.1097/bor.0000000000000046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
34 Desai RJ, Huybrechts KF, Bateman BT, Hernandez-Diaz S, Mogun H, Gopalakrishnan C, Patorno E, Kim SC. Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. Arthritis Rheumatol 2016;68:1183-9. [PMID: 26606742 DOI: 10.1002/art.39521] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
35 O'Toole A, Nwanne O, Tomlinson T. Inflammatory bowel disease increases risk of adverse pregnancy outcomes: A Meta-analysis. Dig Dis Sci. 2015;60:2750-2761. [PMID: 26070523 DOI: 10.1007/s10620-015-3677-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
36 Ngian GS, Briggs AM, Ackerman IN, Van Doornum S. Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation. Int J Rheum Dis 2016;19:834-43. [PMID: 27125255 DOI: 10.1111/1756-185X.12860] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders AG, Pedersen N. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107-124. [PMID: 25602023 DOI: 10.1093/ecco-jcc/jju006] [Cited by in Crossref: 220] [Cited by in F6Publishing: 175] [Article Influence: 44.0] [Reference Citation Analysis]
38 Koslowsky B, Grisaru-Granovsky S, Livovsky DM, Milgrom Y, Goldin E, Bar-Gil Shitrit A. Pregnancy-Onset Inflammatory Bowel Disease: A Subtle Diagnosis. Inflamm Bowel Dis 2018;24:1826-32. [PMID: 29788306 DOI: 10.1093/ibd/izy081] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
39 Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, Cohen RD, Chambers CD, Sandborn WJ; Crohn’s Colitis Foundation Clinical Research Alliance. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology 2021;160:1131-9. [PMID: 33227283 DOI: 10.1053/j.gastro.2020.11.038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
40 Moens A, van Hoeve K, Humblet E, Rahier JF, Bossuyt P, Dewit S, Franchimont D, Macken E, Nijs J, Posen A, Strubbe B, Van Hootegem A, Van Moerkercke W, Vermeire S, Ferrante M; Belgian IBD Research and Development group (BIRD). Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. J Crohns Colitis 2019;13:12-8. [PMID: 30281093 DOI: 10.1093/ecco-jcc/jjy142] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 17.0] [Reference Citation Analysis]
41 Narayan B, Nelson-piercy C. Medical problems in pregnancy. Clin Med 2016;16:s110-6. [DOI: 10.7861/clinmedicine.16-6-s110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
42 Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am 2014;43:495-508. [PMID: 25110255 DOI: 10.1016/j.gtc.2014.05.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
43 Fischer-Betz R, Østensen M. Biologics and small molecules in the management of psoriatic arthritis: Reproduction related issues in female and male patients. Expert Rev Clin Pharmacol 2021;14:979-89. [PMID: 33982647 DOI: 10.1080/17512433.2021.1925536] [Reference Citation Analysis]
44 Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150:734-757.e1. [PMID: 26688268 DOI: 10.1053/j.gastro.2015.12.003] [Cited by in Crossref: 224] [Cited by in F6Publishing: 169] [Article Influence: 37.3] [Reference Citation Analysis]
45 Huang VW, Habal FM. From conception to delivery: managing the pregnant inflammatory bowel disease patient. World J Gastroenterol 2014;20:3495-506. [PMID: 24707132 DOI: 10.3748/wjg.v20.i13.3495] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
46 Mammen A, Korelitz BI. The Management of Severe Ulcerative Colitis During the Third Trimester of Pregnancy. Journal of Clinical Gastroenterology 2015;49:257-8. [DOI: 10.1097/mcg.0000000000000221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Beedie SL, Rore HM, Barnett S, Chau CH, Luo W, Greig NH, Figg WD, Vargesson N. In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. Oncotarget 2016;7:33237-45. [PMID: 27120781 DOI: 10.18632/oncotarget.8909] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
48 Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T, Quantin C, Bardou M. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION). American Journal of Gastroenterology 2018;113:1669-77. [DOI: 10.1038/s41395-018-0176-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 26.3] [Reference Citation Analysis]
49 Ng PY, Ireland DJ, Keelan JA. Drugs to block cytokine signaling for the prevention and treatment of inflammation-induced preterm birth. Front Immunol 2015;6:166. [PMID: 25941525 DOI: 10.3389/fimmu.2015.00166] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
50 Bell SJ, Flanagan EK. Updates in the management of inflammatory bowel disease during pregnancy. Medical Journal of Australia 2019;210:276-80. [DOI: 10.5694/mja2.50062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
51 McConnell RA, Mahadevan U. Pregnancy and the Patient with Inflammatory Bowel Disease: Fertility, Treatment, Delivery, and Complications. Gastroenterol Clin North Am 2016;45:285-301. [PMID: 27261899 DOI: 10.1016/j.gtc.2016.02.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
52 Damas OM, Deshpande AR, Avalos DJ, Abreu MT. Treating Inflammatory Bowel Disease in Pregnancy: The Issues We Face Today. J Crohns Colitis. 2015;9:928-936. [PMID: 26129693 DOI: 10.1093/ecco-jcc/jjv118] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
53 Pons M, Dougados M, Costedoat-Chalumeau N, Briot K, Goupille P, Roux C, Molto A. Pregnancy rates and outcomes in early axial spondyloarthritis: An analysis of the DESIR cohort. Joint Bone Spine 2021;88:105075. [PMID: 32947013 DOI: 10.1016/j.jbspin.2020.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Mahadevan U, Mcconnell RA, Chambers CD. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease. Gastroenterology 2017;152:451-462.e2. [DOI: 10.1053/j.gastro.2016.10.013] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
55 Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Review of Vaccines 2016;15:239-56. [DOI: 10.1586/14760584.2016.1115351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
56 Androulakis I, Zavos C, Christopoulos P, Mastorakos G, Gazouli M. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease. World J Gastroenterol. 2015;21:13205-13211. [PMID: 26715803 DOI: 10.3748/wjg.v21.i47.13205] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
57 Gerosa M, Schioppo T, Meroni PL. Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opinion on Pharmacotherapy 2016;17:1539-47. [DOI: 10.1080/14656566.2016.1197204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 4.4] [Reference Citation Analysis]
58 Selinger CP, Nelson-Piercy C, Fraser A, Hall V, Limdi J, Smith L, Smith M, Nasur R, Gunn M, King A, Mohan A, Mulgabal K, Kent A, Kok KB, Glanville T. IBD in pregnancy: recent advances, practical management. Frontline Gastroenterol 2021;12:214-24. [PMID: 33912333 DOI: 10.1136/flgastro-2019-101371] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Förger F, Villiger PM. Treatment of rheumatoid arthritis during pregnancy: present and future. Expert Review of Clinical Immunology 2016;12:937-44. [DOI: 10.1080/1744666x.2016.1184973] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
60 Pfaller B, José Yepes-Nuñez J, Agache I, Akdis CA, Alsalamah M, Bavbek S, Bossios A, Boyman O, Chaker A, Chan S, Chatzipetrou A, du Toit G, Jutel M, Kauppi P, Kolios A, Li C, Matucci A, Marson A, Bendien S, Palomares O, Rogala B, Szepfalusi Z, Untersmayr E, Vultaggio A, Eiwegger T. Biologicals in atopic disease in pregnancy: An EAACI position paper. Allergy 2021;76:71-89. [PMID: 32189356 DOI: 10.1111/all.14282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
61 Esteve-Solé A, Deyà-Martínez À, Teixidó I, Ricart E, Gompertz M, Torradeflot M, de Moner N, Gonzalez EA, Plaza-Martin AM, Yagüe J, Juan M, Alsina L. Immunological Changes in Blood of Newborns Exposed to Anti-TNF-α during Pregnancy. Front Immunol 2017;8:1123. [PMID: 28983301 DOI: 10.3389/fimmu.2017.01123] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
62 Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Kadioglu Duman M, Meister R, Schaefer C; network of French pharmacovigilance centres. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39. [PMID: 25808588 DOI: 10.1111/bcp.12642] [Cited by in Crossref: 93] [Cited by in F6Publishing: 74] [Article Influence: 15.5] [Reference Citation Analysis]
63 Bröms G, Granath F, Ekbom A, Hellgren K, Pedersen L, Sørensen HT, Stephansson O, Kieler H. Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti–Tumor Necrosis Factor Agents During Pregnancy. Clinical Gastroenterology and Hepatology 2016;14:234-241.e5. [DOI: 10.1016/j.cgh.2015.08.039] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
64 Gerosa M, Meroni PL, Cimaz R. Safety considerations when prescribing immunosuppression medication to pregnant women. Expert Opinion on Drug Safety 2014;13:1591-9. [DOI: 10.1517/14740338.2014.951326] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
65 Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-randone S, Matucci-cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism 2016;45:519-32. [DOI: 10.1016/j.semarthrit.2015.10.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
66 Sandhu VK, Wallace DJ, Weisman MH. Monoclonal Antibodies, Systemic Lupus Erythematosus, and Pregnancy: Insights from an Open-label Study. J Rheumatol 2015;42:728-30. [DOI: 10.3899/jrheum.140952] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]